Drug Profile
Research programme: fluorine-based therapeutics/radiolabelled diagnostics - OcuTerra Therapeutics
Alternative Names: SF 0034Latest Information Update: 10 May 2021
Price :
$50
*
At a glance
- Originator SciFluor Life Sciences
- Developer National Institute of Neurological Disorders and Stroke; OcuTerra Therapeutics
- Class Fluorine compounds; Radiopharmaceutical diagnostics
- Mechanism of Action GABA A receptor agonists; Integrin alphaVbeta3 antagonists; KCNQ potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Amyotrophic lateral sclerosis; Partial epilepsies; Tinnitus
Most Recent Events
- 05 May 2021 SciFluor Life Sciences is now called OcuTerra Therapeutics
- 28 Feb 2019 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA
- 28 Feb 2019 No recent reports of development identified for research development in Tinnitus in USA